In a groundbreaking phase 3 trial, the weekly combination of cagrilintide and semaglutide, termed CagriSema, demonstrated significant weight loss and metabolic improvements in 3,417 overweight or obese adults over 68 weeks. The trial revealed a mean weight loss of 20.4% in those receiving CagriSema, with 91.9% of participants losing at least 5% of their body weight. Additionally, systolic blood pressure decreased, and many participants with prediabetes achieved normoglycemia. While gastrointestinal issues were common, the findings underscore CagriSema’s potential as an effective weight management solution for adults without diabetes and suggest further studies in those with type 2 diabetes.

Source: The New England Journal of Medicine